KRAS and neoplasm: Taken together, dPCR was able to more thoroughly identify the true mutational status of the KRAS gene in PDAC patients compared to Sanger sequencing, even from limited tumor tissues available from FFPE pancreas EUS-FNA biopsy specimens.